Cosmo Pharmaceuticals N.V.
Symbool: COPN.SW
SIX
71.4
CHFMarktprijs vandaag
1009.1513
Koers/Winst Verhouding
14.6994
Koers/Winst Groei Verhouding
1.15B
MRK Kapitalisatie
- 0.01%
DIV Rendement
Cosmo Pharmaceuticals N.V. (COPN-SW) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 50.3 | 241 | 222.2 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 55.1 | 23.6 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 28.5 | 38.6 | 24.5 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 14.2 | 11.5 | 13.1 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 9.3 | 53.6 | 39.7 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 102.2 | 306.1 | 275.8 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 28.6 | 30.3 | 30.5 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 24 | 24 | 24 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 355.6 | 366.8 | 372.7 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 379.6 | 390.8 | 396.7 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 3.3 | -46.9 | 25.4 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 14.7 | 18.6 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 40.3 | 64.5 | 58.4 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 451.8 | 453.5 | 529.7 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 0 | 554 | 759.6 | 805.6 | ||||||||||||||||||||
balance-sheet.row.account-payables | 0 | 8.8 | 10.7 | 11.6 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 171.8 | 0.9 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 2.7 | 3.6 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0.9 | 1.8 | 169 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0.5 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 14.3 | 12.5 | 3.2 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 97.2 | 100.9 | 271.6 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1.3 | 2 | 2.6 | ||||||||||||||||||||
balance-sheet.row.total-liab | 0 | 120.3 | 295.8 | 292.9 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 11.5 | 18.4 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0 | 4.6 | 4.6 | 4.6 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 302.6 | 262.2 | 293.3 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -22.7 | -11.5 | -18.4 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 142.3 | 190.1 | 207.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 426.8 | 456.9 | 505.3 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 554 | 759.6 | 805.6 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 6.9 | 6.9 | 7.4 | ||||||||||||||||||||
balance-sheet.row.total-equity | 0 | 433.6 | 463.8 | 512.7 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 3.3 | 8.3 | 49.1 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 1.1 | 173.6 | 169.9 | ||||||||||||||||||||
balance-sheet.row.net-debt | 0 | -49.2 | -12.2 | -28.6 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 24.5 | 24 | -6.9 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 13.9 | 7.4 | 6 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -21.4 | 5.9 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 2.1 | 1.5 | 9 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -13.3 | -5.1 | -5.1 | |||||||||||||||||||
cash-flows.row.account-receivables | 0 | -14.2 | 3.3 | -7.9 | |||||||||||||||||||
cash-flows.row.inventory | 0 | 1.6 | -6.1 | 0.4 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | 14.2 | -3.3 | 7.9 | |||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -14.9 | 1 | -5.6 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 6.1 | 6.2 | 4.2 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -7.3 | -8.5 | -8.1 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 23.3 | -4.1 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -54 | -1 | -20 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 35.9 | 7.7 | 131.6 | |||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 27.1 | 3.3 | -23.9 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 1.7 | 24.9 | 75.4 | |||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -0.9 | -2.6 | -1.8 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.3 | 0.8 | 5.3 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -24.7 | -19.7 | -11 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -15.6 | -0.8 | 0 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -5.1 | -4.9 | -4.4 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -46.1 | -27.2 | -11.9 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -1.5 | 2.4 | -1 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -12.7 | 12.6 | 75.5 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 185.8 | 198.6 | 185.9 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 198.6 | 185.9 | 110.4 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 33.2 | 12.6 | 13 | |||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -7.3 | -8.5 | -8.1 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 25.9 | 4.1 | 4.9 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 96.7 | 102.1 | 65.1 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 39.3 | 18.8 | 15.1 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 57.4 | 83.3 | 49.9 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 51.7 | 36 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 45.3 | 55.3 | 38.8 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 84.7 | 74 | 54 | ||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 4.5 | 2.9 | 3.1 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 9.2 | 9 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -4.6 | -3.6 | -9.1 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 51.7 | 36 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -4.6 | -3.6 | -9.1 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 9.2 | 9 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 13.6 | 19.4 | 7.4 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 0 | 12.2 | 28.1 | 33.1 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 7.6 | 24.5 | 24 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 6.3 | 7 | 2.3 | ||||||||||||||||||||
income-statement-row.row.net-income | 0 | 1.1 | 17.2 | 21.7 |
Vaak gestelde vragen
Wat is Cosmo Pharmaceuticals N.V. (COPN.SW) totale activa?
Cosmo Pharmaceuticals N.V. (COPN.SW) totale activa is 553980000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.593.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.012.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.126.
Wat is Cosmo Pharmaceuticals N.V. (COPN.SW) nettowinst (netto-inkomen)?
De nettowinst is 1147000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 1079000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 45314000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.